Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Key Resources and Organizations for Precision Medicine Guidelines

MedGenome Strengthens Leadership Team to Drive North American Expansion in Precision Medicine

NCCN Expands Clinical Practice Guidelines for High-Risk Genetic Cancer Assessment

MicrobioTx Launches Gut Function Test (GFT) for Easy, Affordable Gut Health Profiling

Roche to Present Over 40 Abstracts on Blood Disorders at 66th ASH Annual Meeting, Showcasing Advances in Lymphoma Treatments

Hamad Medical Corporation Hosts 3rd Precision Medicine Conference on AI and Genomics Integration

Caris Life Sciences Receives FDA Approval for Groundbreaking MI Cancer Seek™ Diagnostic Assay for Precision Oncology

IWG Proposes New Clinical-Biological Definition for Diagnosing Alzheimer’s Disease

Inify Laboratories and Karolinska Institutet's ProMort Team Partner to Transform Prostate Cancer Diagnostics with AI

Home
/
update
/
details

Illumina Unveils Expanded Oncology Offerings for NovaSeq X Series Customers

NextEdge Admin

05 Aug 2024

2 min 36 sec

Illumina Inc. , a global leader in DNA sequencing technologies, has expanded its oncology offerings for NovaSeq™ X Series customers. The newly verified high-throughput version of TruSight™ Oncology 500 (TSO 500 HT) and the updated TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) liquid biopsy assay are now available. These assays enhance oncology research by enabling comprehensive genomic profiling (CGP) of tissue and liquid biopsy samples with improved sequencing economics, faster run times, and larger batch sizes on the NovaSeq X Series.

Everett Cunningham, Illumina’s chief commercial officer, highlighted the significance of these advancements in driving precision oncology forward. CGP assesses hundreds of genes and immuno-oncology biomarkers from a single sample, aiding therapy selection research and aligning with professional oncology guidelines.

TSO 500 HT on the NovaSeq X Series offers increased throughput and cost efficiencies compared to the NovaSeq 6000 System. Illumina plans to extend TSO 500 HT to the NextSeq 1000 and NextSeq 2000 Systems later this quarter. TSO 500 ctDNA v2 on the NovaSeq X Series delivers a faster, more sensitive, and streamlined liquid biopsy workflow, enabling solid tumor therapy selection research from minimally invasive blood samples.

Laura Knight, global VP of Genomic Services at Almac Diagnostic Services, praised the availability of TSO 500 ctDNA v2 on the NovaSeq X Plus platform for advancing molecular analysis of blood-based biomarkers. The assay offers transformative sequencing economics, a 40% reduction in run times, and sustainable logistics with ambient temperature shipping for consumables. These improvements enable Almac to accelerate oncology research and diagnostic development, marking a significant advancement in precision medicine.